Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Aerie Pharmaceuticals revenue
Aerie Pharmaceuticals's revenue is $194.1 million.
What is Aerie Pharmaceuticals's revenue?
- Aerie Pharmaceuticals's revenue growth from 2018 to 2021 is 702.84%.
- Aerie Pharmaceuticals has 353 employees, and the revenue per employee ratio is $549,954.
- Aerie Pharmaceuticals's peak quarterly revenue was $114.7M in 2021(q4).
- Aerie Pharmaceuticals peak revenue was $194.1M in 2021.
- Aerie Pharmaceuticals annual revenue for 2020 was 83.1M, 18.96% growth from 2019.
- Aerie Pharmaceuticals annual revenue for 2021 was 194.1M, 133.51% growth from 2020.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Aerie Pharmaceuticals historical revenue
Aerie Pharmaceuticals's peak revenue was $194.1M in 2021. The peak quarterly revenue was $114.7M in 2021(q4).
Aerie Pharmaceuticals's revenue increased from $24.2m in 2018 to $194.1M currently. That's a 702.84% change in annual revenue.
Aerie Pharmaceuticals annual revenue
Aerie Pharmaceuticals annual revenue over time
| Fiscal year / year | Aerie Pharmaceuticals revenue |
|---|---|
| 2018 | $24.2M |
| 2019 | $69.9M |
| 2020 | $83.1M |
| 2021 | $194.1M |
Rate Aerie Pharmaceuticals' financial transparency
Aerie Pharmaceuticals annual growth
Aerie Pharmaceuticals saw the greatest revenue growth in 2019, when revenue increased by 189.02%.
Aerie Pharmaceuticals had the lowest revenue growth in 2020, when revenue changed by 18.96%.
Aerie Pharmaceuticals annual growth rate over time
| Year | Aerie Pharmaceuticals growth |
|---|---|
| 2019 | 189%↑ |
| 2020 | 19%↑ |
| 2021 | 134%↑ |
Aerie Pharmaceuticals quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Aerie Pharmaceuticals quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | $2.4M | $7.3M | $14.5M |
| 2019 | $10.9M | $15.8M | $18.5M | $24.7M |
| 2020 | $20.3M | $18.0M | $20.1M | $24.7M |
| 2021 | $23.0M | $27.2M | $29.3M | $114.7M |
| 2022 | $29.8M | $33.3M | $36.1M | - |
Aerie Pharmaceuticals jobs nearby
Do you work at Aerie Pharmaceuticals?
Did Aerie Pharmaceuticals meet its revenue projections?
Aerie Pharmaceuticals financial information
| CEO | Rajkumar Kannan |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 353 |
| Date Founded | 2005 |
| Headquarters | Durham, North Carolina |
| Number of Locations | 5 |
| Revenue | $194.1M |
| Net Income | -$74,810,000 |
| Gross Proft | $167.3M (2021) |
| PE Ratio | -23.66 |
| Tax Rate | -0.0% |
| Market Capitalization | $1.8B |
| Total Assets | $431,391,000 |
| Ticker | AERI |
Aerie Pharmaceuticals jobs you might like
Aerie Pharmaceuticals financing
Aerie Pharmaceuticals received early financing of $10.0M on 2005-10-11.
| Series | Round size | Date |
|---|---|---|
| Series A | $10M | 10/2005 |
| Debt Financing | $5.3M | 09/2010 |
| Series B | $41.4M | 03/2011 |
| Debt Financing | $15M | 08/2013 |
| Post Ipo Equity | $67M | 10/2013 |
| Post Ipo Equity | $125M | 09/2014 |
| Post Ipo Equity | $125M | 09/2016 |
| Post Ipo Debt | $200M | 05/2019 |
| Post Ipo Equity | $316.5M | 09/2019 |
| Post Ipo Equity | $88M | 12/2021 |
Aerie Pharmaceuticals investors
| Investors | Security type |
|---|---|
| TPG Biotech | Series A |
| Osage University Partners | Series B |
| CLARUS VENTURES LLC | Series B |
| SOFINNOVA INVESTMENTS INC | Series B |
| Alta Partners | Series B |
| TPG Biotech | Series B |
| Deerfield Capital Management | Post Ipo Equity |
| Deerfield | Post Ipo Debt |
Aerie Pharmaceuticals competitors
Aerie Pharmaceuticals's top competitor, Zoetis, earned an annual revenue of $9.3B.
Aerie Pharmaceuticals's smallest competitor is Hamilton Marine with revenue of $870.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Zoetis | - | $9.3B | 11,300 | - |
| Incyte | - | $4.2B | 1,600 | - |
| Seagen | - | $2.0B | 900 | - |
| Dicerna Pharmaceuticals | - | $164.3M | 302 | - |
| Kaleido Biosciences | - | $975,000 | 82 | - |
| Intarcia Therapeutics | - | $70.0M | 44 | - |
| Blueprint Medicines | - | $508.8M | 495 | - |
| Inotek Pharmaceuticals | - | $1.0M | 91 | - |
| Karyopharm | - | $145.2M | 442 | - |
| Argos Therapeutics | - | $1.9M | 76 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Aerie Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of Aerie Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Aerie Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Aerie Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Aerie Pharmaceuticals. The data presented on this page does not represent the view of Aerie Pharmaceuticals and its employees or that of Zippia.
Aerie Pharmaceuticals may also be known as or be related to AERIE PHARMACEUTICALS INC, Aerie Pharmaceuticals, Aerie Pharmaceuticals Inc, Aerie Pharmaceuticals, Inc. and aerie.